These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17477886)

  • 1. Major depressive disorder, sleep EEG and agomelatine: an open-label study.
    Quera Salva MA; Vanier B; Laredo J; Hartley S; Chapotot F; Moulin C; Lofaso F; Guilleminault C
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):691-6. PubMed ID: 17477886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
    Quera-Salva MA; Hajak G; Philip P; Montplaisir J; Keufer-Le Gall S; Laredo J; Guilleminault C
    Int Clin Psychopharmacol; 2011 Sep; 26(5):252-62. PubMed ID: 21829106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
    Quera-Salva MA; Lemoine P; Guilleminault C
    Hum Psychopharmacol; 2010 Apr; 25(3):222-9. PubMed ID: 20373473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Agomelatine].
    Tessmer M
    Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
    Descamps A; Rousset C; Millan MJ; Spedding M; Delagrange P; Cespuglio R
    Psychopharmacology (Berl); 2009 Jul; 205(1):93-106. PubMed ID: 19370342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].
    Lôo H; Daléry J; Macher JP; Payen A
    Encephale; 2003; 29(2):165-71. PubMed ID: 14567168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
    Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The results of the Russian multicenter open observational non-comparative study on the efficacy and safety of valdoxan (agomelatin) in the treatment of patients with major depressive disorder and insomnia (the VIVALDI study)].
    Poluéktov MG; Levin YI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):39-44. PubMed ID: 24430033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
    Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
    Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study.
    Gargoloff PD; Corral R; Herbst L; Marquez M; Martinotti G; Gargoloff PR
    Hum Psychopharmacol; 2016 Nov; 31(6):412-418. PubMed ID: 27859669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.